- alias::
  ICD-11_Code::
  tags:: #Disease
- ## Etiology
  background-color:: blue
  - ### Causative Agents
  - ### Risk Factors
- ## Epidemiology
  background-color:: blue
  - ### Incidence
  - ### Prevalence
    - ### Demographics
  - ### Geographic Distribution
- ## Pathophysiology
  background-color:: blue
  - ### Mechanism of Disease
  - ### Affected Systems/Organs
- ## Clinical Features
  background-color:: blue
  - ### Signs and Symptoms
    - #### Symptoms #eye-prof-card #card
      deck:: #Eye
      id:: a8cc2e5c-90dd-4c82-8d22-14a5a66b12bb
      - Mild pain
        logseq.order-list-type:: number
      - Photophobia
        logseq.order-list-type:: number
      - Redness
        logseq.order-list-type:: number
    - #### Signs #eye-prof-card #card
      deck:: #Eye
      id:: ad1ea991-9cc3-440f-9266-3be8950f0d2e
      - Visual Acuity reduced
        logseq.order-list-type:: number
  - ### Stages or Classification
  - ### Diagnostic Criteria
- ## Diagnosis
  background-color:: blue
  - ### Clinical Diagnosis
    - #### Classical Presentation
    - #### Probable Diagnosis
  - ### Laboratory Tests
  - ### Imaging Studies
  - ### Differential Diagnosis
    - [[Acute Angle Closure Glaucoma]]
      id:: 67541f2a-f920-4139-bbd2-9e23ab3a42b2
      - id:: 67541f3e-5249-4a44-8402-70410e14efe4
        | Topic | AAU | AACG |
        |------------------|--------------------------------|--------------------------------|
        | Pain and vision loss | Mild pain and gradual loss of vision | Severe pain and sudden marked loss of vision |
        | Circumcilliary | Mild | Moderate to severe |
        | Cornea | Mild hazy | Hazy |
        | Ant. Chamber | Depth Normal | Shallow |
        | Cell | +++ | +/- |
        | Flare | +++ | + |
        | Pupil | Constricted | Mild dilated |
        | IOP | Less/Normal | Increased |
        | Treatment | Steroid, Mydriatics | Anti-Glaucoma Drugs |
  - ### Confirmation of Diagnosis
- ## Management and Treatment
  background-color:: blue
  - ### Medical Treatment
    - Medications
      - [[Mydriatics]] Topical [[Atropine 1% Sulphate]] [[TDS]]
        logseq.order-list-type:: number
      - [[Steroid]] -> Topical [[Dexamethasone]]
        logseq.order-list-type:: number
    - Mechanism of Action of the Medications
      - [[Atropine 1% Sulphate]] #eye-prof-card #card
        id:: 6755b7b7-3a46-45a7-aa9b-82898d07b7df
        deck:: #Eye
        - Relief Pain
          logseq.order-list-type:: number
        - Prevention and also breakdown of if existing Synachae
          logseq.order-list-type:: number
      - [[Steroid]] -> {{c1 Reduces Inflammation}} #eye-prof-card #card
        deck:: #Eye
        id:: 6755b7e5-3798-4191-a163-e41954f7ce45
  - ### Surgical Options
  - ### Lifestyle and Dietary Recommendations
  - ### Follow-up
- ## Prognosis
  background-color:: blue
  - ### Expected Course
    - #### With Treatment
    - #### Without Treatment
      - ##### Possible Complications
      - ##### Long-Term Effects
  - ### Survival Rates
    - #### With Treatment
    - #### Without Treatment
  - ### Quality of Life Considerations
- ## Prevention
  background-color:: blue
  - ### Health Education
  - ### Community Approach
  - ### Screening Programs
  - ### Lifestyle Modifications
- ## Patient Education and Support
  background-color:: blue
  - ### Educational Resources
  - ### Support Groups
  - ### Counseling Options
- ## Recent Research and Developments
  background-color:: blue
  - ### Ongoing Clinical Trials
  - ### Recent Advances
- ## Key Literature
  background-color:: blue
- ## Guidelines and Protocols
  background-color:: blue
